AyurMaya, a venture capital fund managed by Matrix Capital Management, led a $132m Series C round in Endeavor BioMedicines, a clinical-stage biotechnology company, with participation from Fidelity Management & Research Company, Invus, SymBiosis, Velosity Capital, Woodline Partners, abrdn, Ally Bridge Group, Avidity Partners, Eckuity Capital, Longitude Capital, Omega Funds, Perceptive Advisors, Piper Heartland Healthcare Capital, Silver Arch Bio, and T. Rowe Price Associates. "We appreciate the support from this group of leading life sciences investors, who recognize the tremendous progress we’ve made since our initial funding rounds as well as the life-changing potential of our therapeutic candidates to reverse the trajectory of relentless diseases," John Hood, Endeavor Co-Founder, CEO and Chairman.